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Is c-Src Tyrosine Kinase
a New Target for
Antiarrhythmic Drug Therapy?*
Peng-Sheng Chen, MD, Tomohiko Ai, MD, PHD
ndianapolis, Indiana
c-Src is the cellular homologue of the transforming gene of
Rous sarcoma virus (1). Discovery of this first human
proto-oncogene won Bishop and Varmus the Nobel Prize in
physiology and medicine in 1989. c-Src encodes plasma
membrane-associated tyrosine kinase, which participates in
cell growth and differentiation. It is an integral part of
various signal transduction pathways (2,3). Although c-Src
has been extensively studied for its role in carcinogenesis,
few have thought that it is important in the development of
cardiac arrhythmia. Kieken et al. (4) found that an interac-
tion between c-Src and zonula occludens-1 results in loss of
scaffolding of connexin-43 (Cx43), leaving Cx43 free to
diffuse in myocyte membranes from areas of high Cx43
content (the intercalated disk) to regions of lower Cx43
content (the lateral myocyte membrane). This mechanism
See page 2332
causes Cx43 lateralization in the epicardial border zone and
may play a role in cardiac arrhythmogenesis after myocardial
infarction. In this issue of the Journal, Sovari et al. (5) take this
oncept further by demonstrating that 1-(1,1-dimethylethyl)-
-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
PP1), a c-Src inhibitor, can prevent sudden cardiac death
SCD) in angiotensin-converting enzyme overexpression
ACE8/8) mice. Their findings provide novel insights into the
roarrhythmic action of angiotensin II (Ang-II) and suggest
hat c-Src inhibition may be a new approach to antiarrhythmic
rug therapy.
*Editorials published in the Journal of the American College of Cardiology reflect the
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American College of Cardiology.
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The hypothesis advanced in the present study is that SCD
occurs because elevated Ang-II reduces the expression of
Cx43 in ACE8/8 mice (6). PP1 counteracts this effect,
normalizes Cx43, and thereby prevents SCD. However,
Ang-II does not always decrease Cx43 in experimental
models. For example, 24-h Ang-II treatment of cultured
neonatal rat ventricular myocytes results in doubling of
Cx43 expression (7). Stretch of these cells can increase both
Ang-II and Cx43 (8). The abnormally increased Cx43 can
be reversed in both studies by losartan, an Ang-II receptor
antagonist. In contrast, stretch of the canine right ventricle
for 6 h reduced Cx43 expression and transverse conduction
velocity (9). These in vivo findings are opposite to those
found in neonatal myocytes in vitro (10). Furthermore,
Cx43 reduction and abnormal patterns of distribution are
commonly associated with diseased human ventricles (11).
educed Cx43 is associated with the increased wave breaks
uring ventricular fibrillation in canine model of healed
yocardial infarction (12). Although the relationship of
ng-II and Cx43 may depend on the experimental condi-
ions, the duration of exposure and the concentration of
ng-II used in the experiments, most of the in vivo studies
uggest that there is a reduction of Cx43 in diseased
yocardium. The findings of Sovari et al. (5) are in fact
onsistent with the results of most in vivo experiments.
Effects on the Membrane Ionic Current
In addition to normalization of Cx43, PP1 might have
additional beneficial effects. Previous studies have demon-
strated that Ang-II can modify the function of cardiac ion
channels, including delayed rectifier K currents (IKs) (13),
L-type Ca2 currents (ICa,L) (14), transient outward cur-
ents (Ito) (15), and pacemaker currents (If) (16). c-Src
tyrosine kinase can also modify various ion channels, in-
cluding If (HCN4) (17), Ito (18), and Na
/K–adenosine
triphosphatase (19). Therefore, further studies are war-
ranted to examine whether the antiarrhythmic effects of PP1
is in part due to its effects on the ion channel functions.
Bradycardia and Sudden Cardiac Death
in ACE8/8 Mice
In addition to ventricular arrhythmias, the ACE8/8 mice
may also die of abrupt onset of profound bradycardia.
Because the sinoatrial node (SAN) does not have Cx43, the
mechanism of bradycardia in these mice and the reversal of
the bradycardia phenotype by PP1 are particularly interest-
ing. Several mechanisms may be involved in the develop-
ment of bradycardia in these mice. One is the failure of
automaticity. Some investigators have reported that Ang-II
increases the pacemaker currents (HCN2 and HCN4) in
ventricular myocytes (16), which can promote ventricular
automaticity and ventricular arrhythmias. In contrast,
Ang-II is known to decrease spontaneous firing rate of the
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differential effects of Ang-II on ventricular and SAN auto-
maticity can contribute to the development of ventricular
tachyarrhythmias and sinus bradycardia, respectively, in the
ACE8/8 mice. Another possible mechanism for bradycardia
is the development of conduction block between the SAN
and the atria. The SAN and the atria are connected by
discrete pathways (21). In the center of the SAN, there is no
expression of Cx43 and very little expression of Cx40,
whereas in the periphery of the SAN, Cx43 as well as
connexin 45 is expressed (22). The presence of Cx43 may be
important for the impulse to exit the SAN through the
discrete pathways to activate the surrounding atrial tissues.
It is possible that the reduction of Cx43 at the junction
between the SAN and atria can prevent the SAN from
exciting the atria, resulting in abrupt onset of bradycardia
and SCD. PP1 can salvage this phenotype by increasing
Cx43 to prevent SAN exit block.
Summary
Sovari et al. (5) should be congratulated for documenting
that competition between c-Src tyrosine kinase and Cx43
can reduce Cx43 level and increase the incidence of SCD,
while inhibition of c-Src tyrosine kinase by PP1 can
normalize Cx43 and reduce the incidence of SCD in
ACE8/8 mice. This study, as well as that reported by
Kieken et al. (4), provide new insights into the mechanisms
by which renin-angiotensin system activation increases the
incidence of SCD. These studies also suggest that c-Src
tyrosine kinase may be a new target for antiarrhythmic drug
therapy.
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